190 related articles for article (PubMed ID: 34606913)
1. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus.
Mallet V; Parlati L; Martinino A; Scarano Pereira JP; Jimenez CN; Sakka M; Bouam S; Retbi A; Krasteva D; Meritet JF; Schwarzinger M; Thabut D; Rufat P; Bonnefont-Rousselot D; Sogni P; Pol S; Tsochatzis E;
J Hepatol; 2022 Feb; 76(2):265-274. PubMed ID: 34606913
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants.
Pais R; Lebray P; Rousseau G; Charlotte F; Esselma G; Savier E; Thabut D; Rudler M; Eyraud D; Vezinet C; Siksik JM; Vaillant JC; Hannoun L; Poynard T; Ratziu V
Clin Gastroenterol Hepatol; 2015 May; 13(5):992-9.e2. PubMed ID: 25459558
[TBL] [Abstract][Full Text] [Related]
3. Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.
Zhang X; Wong GL; Yip TC; Cheung JTK; Tse YK; Hui VW; Lin H; Lai JC; Chan HL; Kong AP; Wong VW
Hepatology; 2022 Nov; 76(5):1409-1422. PubMed ID: 35334125
[TBL] [Abstract][Full Text] [Related]
4. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
5. Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis.
Zhang X; Yip TC; Tse YK; Hui VW; Li G; Lin H; Liang LY; Lai JC; Chan HL; Chan SL; Kong AP; Wong GL; Wong VW
Hepatology; 2023 Dec; 78(6):1816-1827. PubMed ID: 37119179
[TBL] [Abstract][Full Text] [Related]
6. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease.
Yilmaz Y; Senates E; Yesil A; Ergelen R; Colak Y
J Diabetes Complications; 2014; 28(3):328-31. PubMed ID: 24602757
[TBL] [Abstract][Full Text] [Related]
7. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.
Canbay A; Kachru N; Haas JS; Sowa JP; Meise D; Ozbay AB
Aliment Pharmacol Ther; 2020 Oct; 52(7):1185-1194. PubMed ID: 33016540
[TBL] [Abstract][Full Text] [Related]
8. Fatty liver index is a predictor of incident diabetes in patients with prediabetes: The PREDAPS study.
Franch-Nadal J; Caballeria L; Mata-Cases M; Mauricio D; Giraldez-García C; Mancera J; Goday A; Mundet-Tudurí X; Regidor E;
PLoS One; 2018; 13(6):e0198327. PubMed ID: 29856820
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.
Wild SH; Walker JJ; Morling JR; McAllister DA; Colhoun HM; Farran B; McGurnaghan S; McCrimmon R; Read SH; Sattar N; Byrne CD;
Diabetes Care; 2018 Feb; 41(2):341-347. PubMed ID: 29167212
[TBL] [Abstract][Full Text] [Related]
10. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.
Ganne-Carrié N; Chaffaut C; Bourcier V; Archambeaud I; Perarnau JM; Oberti F; Roulot D; Moreno C; Louvet A; Dao T; Moirand R; Goria O; Nguyen-Khac E; Carbonell N; Antonini T; Pol S; de Ledinghen V; Ozenne V; Henrion J; Péron JM; Tran A; Perlemuter G; Amiot X; Zarski JP; Beaugrand M; Chevret S;
J Hepatol; 2018 Dec; 69(6):1274-1283. PubMed ID: 30092234
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease.
Newton KP; Wilson LA; Crimmins NA; Fishbein MH; Molleston JP; Xanthakos SA; Behling C; Schwimmer JB;
Clin Gastroenterol Hepatol; 2023 May; 21(5):1261-1270. PubMed ID: 35709934
[TBL] [Abstract][Full Text] [Related]
12. Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study.
Vaz J; Eriksson B; Strömberg U; Buchebner D; Midlöv P
BMC Gastroenterol; 2020 Apr; 20(1):84. PubMed ID: 32245414
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan.
Akuta N; Kawamura Y; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
BMC Gastroenterol; 2018 Nov; 18(1):165. PubMed ID: 30400829
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
15. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
Ampuero J; Aller R; Gallego-Durán R; Crespo J; Calleja JL; García-Monzón C; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Albillos A; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Guerra MH; Augustín S; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero Gómez M;
J Hepatol; 2020 Jul; 73(1):17-25. PubMed ID: 32147361
[TBL] [Abstract][Full Text] [Related]
16. Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: A retrospective cohort study.
Raverdy V; Chatelain E; Lasailly G; Caiazzo R; Vandel J; Verkindt H; Marciniak C; Legendre B; Bauvin P; Oukhouya-Daoud N; Baud G; Chetboun M; Vantyghem MC; Gnemmi V; Leteurtre E; Staels B; Lefebvre P; Mathurin P; Marot G; Pattou F
Obesity (Silver Spring); 2023 Dec; 31(12):3066-3076. PubMed ID: 37987186
[TBL] [Abstract][Full Text] [Related]
17. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
[TBL] [Abstract][Full Text] [Related]
19. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.
Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Targher G; Lonardo A
Int J Mol Sci; 2016 Mar; 17(3):355. PubMed ID: 27005620
[TBL] [Abstract][Full Text] [Related]
20. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]